Gene delivery of human apolipoprotein E alters brain Abeta burden in a mouse model of Alzheimer's disease.

Apolipoprotein E (apoE) alleles are important genetic risk factors for Alzheimer's disease (AD), with the epsilon4 allele increasing and the epsilon2 allele decreasing risk for developing AD. ApoE has been shown to influence brain amyloid-beta peptide (Abeta) and amyloid burden, both in humans and in transgenic mice. Here we show that direct intracerebral administration of lentiviral vectors expressing the three common human apoE isoforms differentially alters hippocampal Abeta and amyloid burden in the PDAPP mouse model of AD. Expression of apoE4 in the absence of mouse apoE increases hippocampal Abeta(1-42) levels and amyloid burden. By contrast, expression of apoE2, even in the presence of mouse apoE, markedly reduces hippocampal Abeta burden. Our data demonstrate rapid apoE isoform-dependent effects on brain Abeta burden in a mouse model of AD. Gene delivery of apoE2 may prevent or reduce brain Abeta burden and the subsequent development of neuritic plaques.

[1]  C. Kessler,et al.  Apolipoprotein E4 promotes the early deposition of Aβ42 and then Aβ40 in the elderly , 2000, Acta Neuropathologica.

[2]  John Hardy,et al.  Genetic dissection of Alzheimer's disease and related dementias: amyloid and its relationship to tau , 1998, Nature Neuroscience.

[3]  D. Selkoe.  Alzheimer's disease: genes, proteins, and therapy. , 2001, Physiological reviews.

[4]  L. Mucke,et al.  Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein , 1995, Nature.

[5]  R. Mahley,et al.  Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. , 1988, Science.

[6]  A. Fagan,et al.  Human and Murine ApoE Markedly Alters Aβ Metabolism before and after Plaque Formation in a Mouse Model of Alzheimer's Disease , 2002, Neurobiology of Disease.

[7]  A D Roses,et al.  Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[8]  G. Getz,et al.  Effect of Apolipoprotein E on Neurite Outgrowth and β‐Amyloid‐Induced Toxicity in Developing Rat Primary Hippocampal Cultures , 1997, Journal of neurochemistry.

[9]  T. Lanz,et al.  Dendritic spine loss in the hippocampus of young PDAPP and Tg2576 mice and its prevention by the ApoE2 genotype , 2003, Neurobiology of Disease.

[10]  F. Gage,et al.  Neprilysin Gene Transfer Reduces Human Amyloid Pathology in Transgenic Mice , 2003, The Journal of Neuroscience.

[11]  A. Roses,et al.  Neurodegeneration in the Central Nervous System of apoE-Deficient Mice , 1995, Experimental Neurology.

[12]  F. Gage,et al.  Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[13]  A. Fagan,et al.  Astrocyte lipoproteins, effects of apoE on neuronal function, and role of apoE in amyloid‐β deposition in vivo , 2000, Microscopy research and technique.

[14]  Fred H. Gage,et al.  Development of a Self-Inactivating Lentivirus Vector , 1998, Journal of Virology.

[15]  A. Roses,et al.  Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. , 1994, The Journal of clinical investigation.

[16]  M. Mattson.  Pathways towards and away from Alzheimer's disease , 2004, Nature.

[17]  R J Miller,et al.  Isoform-Specific Effect of Apolipoprotein E on Cell Survival and β-Amyloid-Induced Toxicity in Rat Hippocampal Pyramidal Neuronal Cultures , 1998, The Journal of Neuroscience.

[18]  A. D. Roses,et al.  Association of apolipoprotein E allele €4 with late-onset familial and sporadic Alzheimer’s disease , 2006 .

[19]  S. Paul,et al.  Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition , 1997, Nature Genetics.

[20]  C. Kessler,et al.  Apolipoprotein E4 Promotes Incipient Alzheimer Pathology in the Elderly , 1998, Alzheimer disease and associated disorders.

[21]  S. Paul,et al.  Neuroanatomical Abnormalities in Behaviorally Characterized APPV717F Transgenic Mice , 2000, Neurobiology of Disease.

[22]  A. Roses,et al.  Apolipoprotein E and Alzheimer's disease. , 1996, Annual review of neuroscience.

[23]  Russell E Jacobs,et al.  Dentate gyrus volume is reduced before onset of plaque formation in PDAPP mice: A magnetic resonance microscopy and stereologic analysis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[24]  L Naldini,et al.  Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector , 1997, Journal of virology.

[25]  A. M. Saunders,et al.  Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease , 1994, Nature Genetics.

[26]  D. Trono,et al.  A Third-Generation Lentivirus Vector with a Conditional Packaging System , 1998, Journal of Virology.

[27]  A. Fagan,et al.  Apolipoprotein E-containing High Density Lipoprotein Promotes Neurite Outgrowth and Is a Ligand for the Low Density Lipoprotein Receptor-related Protein* , 1996, The Journal of Biological Chemistry.

[28]  J. Trojanowski,et al.  Traumatic brain injury in young, amyloid‐β peptide overexpressing transgenic mice induces marked ipsilateral hippocampal atrophy and diminished Aβ deposition during aging , 1999 .

[29]  Xin Wu,et al.  Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model , 2002, Nature Neuroscience.

[30]  S. Paul,et al.  Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-β peptides , 2004, Nature Medicine.

[31]  B. Hyman,et al.  Apolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactions , 1993, Neuron.

[32]  N. Maeda,et al.  Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoe*2. , 1998, The Journal of clinical investigation.

[33]  N. Maeda,et al.  Targeted Replacement of the Mouse Apolipoprotein E Gene with the Common Human APOE3 Allele Enhances Diet-induced Hypercholesterolemia and Atherosclerosis* , 1997, The Journal of Biological Chemistry.

[34]  A. Fagan,et al.  Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[35]  G. Getz,et al.  Association of human, rat, and rabbit apolipoprotein E with β‐amyloid , 1997, Journal of neuroscience research.

[36]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[37]  F. Bloom,et al.  Selective vulnerability of dentate granule cells prior to amyloid deposition in PDAPP mice: digital morphometric analyses. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[38]  J. Poirier,et al.  The neurobiology of apolipoproteins and their receptors in the CNS and Alzheimer's disease , 1998, Brain Research Reviews.

[39]  J. Gilbert,et al.  Specific regional transcription of apolipoprotein E in human brain neurons. , 1999, The American journal of pathology.

[40]  V. Zannis,et al.  Intracellular modifications of human apolipoprotein E. , 1986, The Journal of biological chemistry.

[41]  M. Pericak-Vance,et al.  Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[42]  Simon M Laws,et al.  Expanding the association between the APOE gene and the risk of Alzheimer's disease: possible roles for APOE promoter polymorphisms and alterations in APOE transcription , 2003, Journal of neurochemistry.